HIND - Vyome Therapeutics Total Debt to Capital
This chart illustrating the total debt-to-equity ratio for Vyome Holdings Inc (HIND) shows a value of 0.00. Vyome Holdings Inc (HIND) is currently in the pre-commercial stage, where a lack of sales makes the business dependent on external research funding. Vyome Holdings Inc (HIND) is currently developing a line of immunological agents for skin therapy, which are presently undergoing clinical trials. The organization is creating unique treatment methods for severe dermatological infections to which microorganisms do not develop resistance.
%20-%20All%20Debt%20to%20Shareholders'%20Equity%20Ratio&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_HIND_-_Vyome-Holdings-Inc_-_All-Debt-to-Shareholders-Equity-Ratio "HIND (Vyome Holdings Inc) Total Debt to Capital history from 08/16/2025 to 11/01/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Vyome Holdings Inc
- price and consensus price forecast:
- market capitalization statistics:
- book capitalization indicators:
- company total debt and liquidity indicators:
Debt to Equity Vyome Holdings Inc|HIND - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Vyome Holdings Inc|HIND - Company Aggregate Debts|Debt to Book Value Vyome Holdings|HIND - Company Long-Term Loans and Borrowings|Company Short-Term Debts Vyome Holdings|Quick Liquidity reshapelifesciences.com
- earnings and valuation multiples information:
Basic company analysis:Vyome Holdings
To stress-test assets, an investor evaluates business dependence on external loans via the total liabilities-to-equity ratio. For Vyome Holdings Inc (HIND), which develops Lap-Band systems and obesity medications, the debt-to-equity ratio dynamics determine the balance between aggressive innovation financing and default risk during market volatility.
Competitor analysis for Vyome Holdings Inc
Debt to Equity argenx|BioNTech Inc. - Aggregate Debt to Equity|Total Debt to Capital ABVX|ADMA (ADMA Corp) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital PTGX (Protagonist Therapeutics)|Total Debt to Capital immunovant.com IMVT|KNSA - Debt to Equity|All Debt to Shareholders' Equity Ratio GRFS (Grifols SA)|Adaptive Biotechnologies Corp (ADPT) - Debt to Equity|Total Debt to Equity Ratio Celldex Corp|AUPH (Aurinia Pharmaceuticals) - Total Debt to Capital|Total Debt to Capital biocryst.com|Total Debt to Equity Ratio VERA (Vera Therapeutics)|DNTH (Dianthus Therapeutics Inc) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital PHVS (Pharvaris Corp)|Total Debt to Capital Coefficient AbCellera (ABCL)|TRML - Debt to Equity|precigen.com (PGEN) - Total Debt to Equity Ratio|Pharming Group (PHAR) - Debt to Equity|Total Debt to Equity Ratio Nektar Therapeutics Inc|Total Debt to Equity Ratio UPB|Total Debt to Capital Zenas Corp|Debt to Equity Immunome, Inc. (IMNM)|gossamerbio.com - Debt to Equity Ratio|Total Debt to Capital KALV (KalVista Pharmaceuticals, Inc.)|Septerna, Inc. (SEPN) - Debt to Capital|PVLA: Total Debt to Equity Ratio|SVRA: Debt to Equity|RIGL (Rigel Pharmaceuticals) - Total Debt to Equity Ratio|Debt to Capital anaptysbio.com (ANAB)|Debt to Equity Astria Therapeutics, Inc.|Debt to Capital enGene Holdings Inc ENGN|Debt to Equity RAPT Therapeutics, Inc. (RAPT)|Total Debt to Equity Ratio aerovatetx.com JBIO|Total Debt to Capital ACRS (Aclaris Therapeutics)|kyvernatx.com (KYTX) - Debt to Capital|TLSA: Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio CABA (Cabaletta Bio Inc.)|VTYX: Total Debt to Capital|Theratechnologies, Inc - All Debt to Shareholders' Equity Ratio|Debt to Equity Avalo Therapeutics, Inc|Debt to Capital eledon.com ELDN|Debt to Equity Agenus Inc. (AGEN)|Debt to Equity CLYM (Climb Bio Inc.)|Total Debt to Capital ZURA (Zura Bio Limited)|ATYR: Debt to Equity Ratio|Adagene Corp - Total Debt to Capital|Total Debt to Capital Coefficient ImageneBio Inc IMA|shattucklabs.com (STTK) - Debt to Equity|Debt to Equity Ratio EQ|CNTB (Connect Biopharma Holdings) - Total Debt to Capital|IMUX - Debt to Capital Ratio|Debt to Equity Atara Biotherapeutics (ATRA)|Total Debt to Capital Coefficient inflarx.de|X4 Pharmaceuticals, Inc. - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio ACET|Celularity Corp - Total Debt to Capital|Total Debt to Capital Coefficient INmune Bio Corporation INMB|Barinthus Biotherapeutics (BRNS) - Debt to Equity|Debt to Equity Ratio KZR|SABS (SAB Biotherapeutics, Inc.) - Total Debt to Capital|Total Debt to Equity Ratio Akari Therapeutics PLC (AKTX)|Total Debt to Capital ENLV|QTTB (q32bio.com) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital GOVX (GeoVax Labs, Inc.)|Total Debt to Capital Coefficient edesabiotech.com (EDSA)|IBIO - Debt to Equity|CARM (Carisma Therapeutics) - Debt to Equity Ratio|XTLB: Total Debt to Capital|Debt to Equity Ratio BOLT|Debt to Equity HCW Biologics, Inc.|Aptevo - Aggregate Debt to Equity|Total Debt to Capital AIM|ADTX (aditxt.com) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital GRI (GRI Bio Corp)|Total Debt to Capital XORTX Corp XRTX|REVB - Debt to Equity|All Debt to Shareholders' Equity Ratio INDP (indaptusrx.com)|Scinai Immunotherapeutics Ltd. (SCNI) - Debt to Equity|Total Debt to Equity Ratio CalciMedica|AFMD (Affimed NV) - Total Debt to Capital|Total Debt to Capital Allakos Therapeutics|Total Debt to Equity Ratio HOOK (HOOKIPA Pharma Inc.)|IGMS (igmbio.com) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital ITOS (iTeos Therapeutics, Inc.)|Total Debt to Capital Coefficient Ocean Biomedical Inc (OCEA)|TCBP - Debt to Equity|Third Harmonic Bio Inc (THRD) - Total Debt to Equity Ratio